An Open-label, Single-arm Phase 2 Safety Study of Nivolumab in Participants with Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 12 Feb 2018 Status changed from not yet recruiting to recruiting.
- 05 Oct 2017 New trial record